Liver Disorder Articles & Analysis
19 news found
Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH) under Award Number R42NS120548. ...
Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH) under Award Number R42NS120548. ...
-Shareholder-Letter-220406.pdf Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH) under Award Number R42NS120548. ...
Capitalizing on significant advances in computational biology and drug discovery, the Company has applied its proprietary computational SEE-Tx® platform to generate its lead programs in GBA1 Parkinson’s disease, Gaucher disease as well as four additional programs to advance the treatment of lysosomal storage disorders. In addition, the Company has leveraged SEE-Tx to ...
The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, CNS disorders and liver diseases. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, Arcellx ...
The Company was recently awarded a three-year $2.97 million Phase 2 STTR Study Grant by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). ...
About KLS-13019 KLS-13019 is Neuropathix patented lead clinical target for the potential treatment of a range of neurotoxic, neurodegenerative and neuropathic pain disorders, beginning with CIPN. KLS-13019 is a monotherapeutic non-opioid cannabinoid derivative that has been shown to prevent and reverse neuropathic pain in pre-clinical animal studies. ...
(“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, today announces that its wholly owned subsidiary, Kannalife Sciences, Inc. has received a notice of award from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) for a $2.97 million Phase 2 ...
Witek is an experienced scientific leader in the field of liver biology with a strong track record of success working in the biotech industry and research space. ...
We now move into the commercial phase of development for LEA™ and, as such, we have now formed Dermique to capitalize on LEA™ as well as the underlying brands we intend to bring to the market for a variety of disorders and skin problems. Our preclinical studies have demonstrated, alongside certain isolated test subjects, that LEA™ is simply better than CBD for ...
WO/2021/097351 “Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin Disorders.” One of the compounds disclosed as part of this PCT Patent is the Company’s proprietary ingredient LEA™. ...
“These key pharmacological benefits open the door to a host of other peripheral and central nervous system diseases and disorders as well.” KLS-13019 leads Kannalife’s intellectual property portfolio of novel monotherapeutic molecules (“KLS Family”), which have been proven capable of acting as neuroprotective agents and have the potential to treat a ...
Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), ...
Kannalife, Inc. is a biopharmaceutical medchem company focused on the development of proprietary and patented novel, monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), ...
When these studies are completed, we believe we will have a superior compound in treating keratinocyte-derived cytokine related skin disorders. After that, we would be really interested to see how Atopidine™ works with and compares to Kevzara (sarilumab) from Sanofi-Regeneron and Roche’s Actemra (tocilizumab), both IL-6 human monoclonal antibodies used in treating ...
About KLS-13019 KLS-13019 is Kannalife’s leading proprietary investigational CBD-like product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). ...
Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), ...
Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders – including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), ...
This study specifically investigated cyanobacterial blooms and liver damage, for which there is already evidence of a connection. To investigate the risk further, this US-wide study tested the hypothesis that contamination by cyanobacterial blooms is a risk factor for nonalcoholic liver disease. This is the most common liver ...